PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Feb 14, 2019
SOUTH PLAINFIELD, N.J. , Feb. 14, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2018 financial results and provide an update on the company's business and outlook on
Additional Formats
Feb 13, 2019
- STRIVE Awards have Supported Over 20 Projects in 15 Countries- -Grant Proposals from Nonprofit Patient Advocacy Organizations Due April 30- SOUTH PLAINFIELD, N.J. , Feb. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the fifth annual STRIVE grant
Additional Formats
Jan 31, 2019
- $500,000 funding to improve Duchenne muscular dystrophy diagnosis and screening in 2019 - SOUTH PLAINFIELD, N.J. , Jan. 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today launched PRIORITY, an annual funding program for innovative research.
Additional Formats
Jan 25, 2019
SOUTH PLAINFIELD, N.J. , Jan. 25, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on January 22, 2019 it approved non-statutory stock options to purchase an aggregate of 170,050 shares of its common stock to 24 new employees.
Additional Formats
Jan 23, 2019
SOUTH PLAINFIELD, N.J. , Jan. 23, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 6,720,000 shares of its common stock at a public offering price of $30.20 per share, before underwriting discounts.
Additional Formats
Jan 22, 2019
SOUTH PLAINFIELD, N.J. , Jan. 22, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $200 million of shares of its common stock. All of the shares in the offering are to be sold by PTC.
Additional Formats
Jan 07, 2019
SOUTH PLAINFIELD, N.J. , Jan. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Dr. Mark Pykett to Chief Scientific Officer and Dr. Neil Almstead to Chief Technical Operations Officer. "Achievement of our long-term strategy requires accelerating our
Additional Formats
Jan 07, 2019
- Multiple products to be launched by 2023 potentially generating ~$1.5 billion revenue annually- - Plan to submit BLA in 2H 2019 for AADC gene therapy program - - Risdiplam regulatory filing targeted for 2H 2019 - - TEGSEDI™ filed in Brazil for expected approval in 2019 - - Duchenne franchise
Additional Formats
Jan 02, 2019
SOUTH PLAINFIELD, N.J. , Jan. 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the J.P. Morgan Healthcare Conference on Tuesday, January 8 th at 5 p.m. PST . The presentation will be webcast live on the Events and
Additional Formats
Dec 20, 2018
SOUTH PLAINFIELD, N.J. , Dec. 20, 2018 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on December 17, 2018 it approved non-statutory stock options to purchase an aggregate of 24,500 shares of its common stock to 5 new employees.
Additional Formats